Is BDX a buy or sell right now?

Innellis AI committee rates Becton Dickinson Watch with a composite score of 58/100.

Do analysts agree on BDX?

6 AI analysts evaluated Becton Dickinson, with 67 percent agreement on the overall direction.

What is the near-term upside for BDX?

Based on nearby resistance levels, Becton Dickinson has a near-term technical upside of +5.0 percent. This is a support/resistance measure, not a price target.

BDX · NYSE · STOCK

Becton Dickinson (BDX) Stock Analysis

Healthcare Updated October 10, 2026

$183.72

52W $127.59 – $193.07

AI Score

58/100

Market Cap

$50.63B

P/E Ratio

55.3

Beta

0.28

Is BDX Bullish or Bearish?

Mixed. Innellis AI committee rates Becton Dickinson (BDX) Watch with a composite score of 58/100 , based on 6 analysts with 67% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy: Requires a committee score of 60.0 — +2.09 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce: Requires the score to fall below 40.0 — -17.91 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Risk Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case

3 consecutive earnings beats -- consistent execution — Growth
Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
MACD histogram positive -- bullish momentum — Technical
Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
News sentiment is positive (+0.27 across 28 articles, 14d) — News

Bear Case

P/E of 52.7 is expensive by classic value standards — Value
ROE of only 3.8% -- cheap may mean cheap for a reason — Value
Revenue declining -2.6% YoY -- this is not a growth story right now — Growth
EPS declining -40.4% YoY despite any revenue growth — Growth

Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.

Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026

Overall Committee Score

58/100

Agreement

67%

Analysts

Conviction

Moderate

Sector Rank

Top 45%

of 192 Healthcare peers

Value Analyst bearish

35 / 100 · Moderate confidence

Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals

− P/E of 52.7 is expensive by classic value standards

Growth Analyst neutral

50 / 100 · High confidence

Moderate growth -- present but not remarkable

+ 3 consecutive earnings beats -- consistent execution

− Revenue declining -2.6% YoY -- this is not a growth story right now

Technical Analyst bullish

61 / 100 · High confidence

Price action is constructive -- trend and momentum agree

+ MACD histogram positive -- bullish momentum

Risk Analyst bullish

70 / 100 · Low confidence

Risk profile is manageable -- leverage, volatility, and event exposure all look contained

Macro Analyst bullish

65 / 100 · Low confidence

Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor

News Analyst bullish

66 / 100 · Low confidence

News flow and recent filings/analyst actions are net positive

+ News sentiment is positive (+0.27 across 28 articles, 14d)

Portfolio Manager bearish

30 / 100 · Moderate confidence

The existing book itself argues for caution here, independent of how good this specific stock looks

− Sector concentration is already high (HHI 2796.97)

Open Full Terminal →

Investment Thesis Evolution

Committee score strengthened from 54.0 to 57.9.

Conviction changed from contested to moderate.
Committee agreement increased sharply from 40% to 67%.
New bearish signals: 1 appeared.
Bullish support removed: 1 signal(s) disappeared.
New bullish signals: 2 appeared.
Bearish pressure eased: 2 signal(s) disappeared.
Analyst(s) changed stance: Technical Analyst.
New analyst(s) joined: Risk Analyst.

Analyst-level changes:

News Analyst: +1 bullish signal(s).
Risk Analyst joined: bullish at 70.
Technical Analyst: stance neutral->bullish; score 54->61 (+8); +1 bullish signal(s).
Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)

61.2

Neutral

MACD Histogram

0.040

Bullish Momentum

Trend Direction

Sideways

Weekly: Sideways

Market Structure

Hh Hl

Support

$178.14

Resistance

$192.93

Bollinger %B

0.75

Inside Bands

Price vs Moving Averages

EMA 9

$181.31 Above

EMA 21

$181.33 Above

EMA 50

$178.25 Above

EMA 200

$173.27 Above

Fundamental Analysis

Valuation

Growth

Profitability

Financial Health

Cash Flow

Valuation

P/E Ratio 55.3×

P/B Ratio 2.07×

PEG Ratio -1.37

Dividend Yield 2.16%

52W High $193.07

52W Low $127.59

Quality & Growth

ROE 660.9%

ROA 303.3%

Gross Margin 4612.0%

Operating Margin 982.8%

Revenue Growth YoY —

Debt / Equity 0.69

AI Fundamental Assessment

P/E ratio of 55.3 (rich relative to a 15-40x range); Price-to-book of 2.1x; PEG ratio of -1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 6.6%; Return on assets of 3.0%; Net margin of 4.5%; Gross margin of 46.1%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 0.69; Free cash flow per share is positive (9.48); Most recent quarter beat estimates by 1.8%; 3 consecutive earnings beats; EPS growth accelerating (-0.3% -> +11.4% QoQ); Average YoY EPS growth of -12.2%; Analyst estimates rising over recent quarters

Get the Full BDX Analysis

Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A

Open in Terminal →